Capricor Therapeutics, Inc. (CAPR)

35.01 +0.29 (+0.84%) USD  |  NASDAQ  |  Apr 15, 16:00
35.13 +0.12 (+0.34%) After-Hours: 20:00
More

Capricor Therapeutics Research and Development Expense (Annual) : 83.50M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for CAPR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Inovio Pharmaceuticals, Inc. 52.79M
Vaxart, Inc. 201.58M
Allogene Therapeutics, Inc. 137.79M
REGENXBIO, Inc. 212.68M
Replimune Group, Inc. 191.22M